VEGFA and hepatocellular carcinoma: Even though immune checkpoint inhibitors are promising new drugs in the therapeutic landscape of HCC and have shown a survival benefit when combined with the antivascular endothelial growth factor (VEGF) antibody bevacizumab, there is still an unmet need for more effective treatment strategies, since immunotherapy is not effective or applicable in all HCC patients [9,10].